Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05385224 · ClinicalTrials.gov registry record · NA
PillSense System for Detecting UGI Bleed
A NA study of UGI Bleed and Upper Gastrointestinal Bleeding, sponsored by EnteraSense Limited.
- Completed
- Registry status
- NA
- Development phase
- 131
- Enrollment target
- 1
- Study location
NCT05385224 is a NA study of UGI Bleed and Upper Gastrointestinal Bleeding that has completed, run by EnteraSense Limited. The registered enrollment target is 131 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05385224, a NA study of UGI Bleed and Upper Gastrointestinal Bleeding, has completed, sponsored by EnteraSense Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 131 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, non-randomized, open-label clinical investigation to evaluate feasibility, effectiveness and safety of the PillSense System, the transit of the PillSense Capsule through the GI tract, patient tolerability of the PillSense Capsule, and blood detection.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PillSense
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2021-12-10 |
| Est. Completion | 2022-09-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05385224
The ClinicalTrials.gov registry entry for NCT05385224 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EnteraSense Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with UGI Bleed appearing as the primary indexed condition, and to 1 intervention - of which PillSense is the first listed.
NCT05385224 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05385224 about?
NCT05385224 is a clinical study titled "PillSense System for Detecting UGI Bleed". This is a prospective, non-randomized, open-label clinical investigation to evaluate feasibility, effectiveness and safety of the PillSense System, the transit of the PillSense Capsule through the GI tract, patient tolerability of the PillSense Capsule, and blood detection.
What is the current status of trial NCT05385224?
This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2021-12-10. Estimated completion is 2022-09-13.
What conditions does trial NCT05385224 study?
This clinical trial studies the following conditions: UGI Bleed, Upper Gastrointestinal Bleeding, Upper Gastrointestinal Bleed.
What interventions are being tested in trial NCT05385224?
The interventions under investigation include: PillSense (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05385224?
This trial is sponsored by EnteraSense Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05385224 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.